State class actions alleging that drug makers labeled their products with deceptive expiration dates met the amount-in-controversy requirement for removal under the Class Action Fairness Act, the 8th U.S. Circuit Court of Appeals has ruled in reversing judgment.Read More »
Drug maker Pfizer violated the Racketeer Influenced and Corrupt Organizations Act by engaging in a fraudulent marketing scheme promoting the epilepsy drug Neurontin for “off-label” uses, the 1st U.S. Circuit Court of Appeals has ruled in affirming judgment.Read More »
At the same time that Pfizer is reporting that it has settled 80 percent of product liability claims involving the smoking cessation drug Chantix, the federal judge in charge of the multidistrict litigation is sending the remaining cases on his ...Read More »
Pfizer has avoided a bellwether trial scheduled to begin this month in the Chantix multidistrict litigation by settling with an Alabama man who claimed he became suicidal after taking the smoking-cessation drug.Read More »
A woman who developed breast cancer after taking combination hormone therapy drugs including Premarin, Provera and Prempro for 15 years won a $5 million award against drug companies Wyeth and Upjohn this month.Read More »
Drug maker Pfizer has set aside an additional $330 million to cover its liability for hormone-replacement therapy drugs like Prempro, Premarin and Provera, indicating in a regulatory filing that total payouts for those claims will probably approach $1.2 billion.Read More »
The anti-nausea drug Reglan and its generic counterparts were the drugs most frequently cited in litigation in 2011, according to a consumer watchdog’s latest analysis of Food and Drug Administration statistics.
Tagged with: Accutane adverse events Avandia Bayer Chantix Coumadin drug litigation FDA Food and Drug Administration GlaxoSmithKline Hoffman-LaRoche Institute for Safe Medication Practices Johnson & Johnson Levaquin Pfizer Pradaxa prescription drugs Reglan Wyeth Yasmin YazRead More »